NYSE - Nasdaq Real Time Price • USD
Merck & Co., Inc. (MRK)
As of 9:56 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 16 | 24 | 23 |
| Avg. Estimate | 1.87 | 2.16 | 8.56 | 9.83 |
| Low Estimate | 1.76 | 1.85 | 8.44 | 9.3 |
| High Estimate | 2.12 | 2.27 | 8.78 | 10.46 |
| Year Ago EPS | 1.4 | -2.06 | 1.51 | 8.56 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 14 | 24 | 23 |
| Avg. Estimate | 15.2B | 15.89B | 63.83B | 68.17B |
| Low Estimate | 14.87B | 15.34B | 62.72B | 66.08B |
| High Estimate | 15.68B | 16.34B | 64.82B | 71.03B |
| Year Ago Sales | 13.78B | 15.04B | 60.12B | 63.83B |
| Sales Growth (year/est) | 10.30% | 5.70% | 6.20% | 6.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 1.32 | -2.18 | 1.78 | -0.11 |
| EPS Actual | 1.4 | -2.06 | 1.94 | 0.03 |
| Difference | 0.08 | 0.12 | 0.16 | 0.14 |
| Surprise % | 6.10% | 5.50% | 9.00% | 127.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.87 | 2.16 | 8.56 | 9.83 |
| 7 Days Ago | 1.94 | 2.11 | 8.56 | 9.8 |
| 30 Days Ago | 2.06 | 2.02 | 8.58 | 9.77 |
| 60 Days Ago | 2.05 | 2.01 | 8.58 | 9.76 |
| 90 Days Ago | 1.99 | 2.06 | 8.49 | 9.56 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 3 | 2 | 2 |
| Up Last 30 Days | 3 | 11 | 9 | 10 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 4 | -- | 1 | -- |
Growth Estimates
| CURRENCY IN USD | MRK | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 33.60% | -- | -- | 1.50% |
| Next Qtr. | 204.90% | -- | -- | 11.40% |
| Current Year | 466.90% | -- | -- | 5.20% |
| Next Year | 14.80% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 67.38% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -11.64% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
| Maintains | Berenberg: Buy to Buy | 4/8/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 |
| Reiterates | Truist Securities: Buy to Buy | 3/28/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/27/2024 |
Related Tickers
JNJ Johnson & Johnson
147.59
-0.64%
BMY Bristol-Myers Squibb Company
45.45
-6.98%
ABBV AbbVie Inc.
167.63
-0.10%
PFE Pfizer Inc.
25.93
-1.31%
LLY Eli Lilly and Company
725.32
-0.94%
AMGN Amgen Inc.
270.92
-0.77%
OGN Organon & Co.
18.58
-0.69%
AZN AstraZeneca PLC
75.23
+5.66%
GILD Gilead Sciences, Inc.
66.60
-0.72%
NVS Novartis AG
98.59
+0.24%